10x Genomics Dl Stock Current Valuation
| 1KJ Stock | EUR 12.61 0.07 0.56% |
Valuation analysis of 10X GENOMICS DL helps investors to measure 10X GENOMICS's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that 10X GENOMICS's price fluctuation is slightly risky at this time. Calculation of the real value of 10X GENOMICS DL is based on 3 months time horizon. Increasing 10X GENOMICS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the 10X stock is determined by what a typical buyer is willing to pay for full or partial control of 10X GENOMICS DL. Since 10X GENOMICS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of 10X Stock. However, 10X GENOMICS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.61 | Real 12.07 | Hype 12.61 |
The real value of 10X Stock, also known as its intrinsic value, is the underlying worth of 10X GENOMICS DL Company, which is reflected in its stock price. It is based on 10X GENOMICS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of 10X GENOMICS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of 10X GENOMICS DL helps investors to forecast how 10X stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 10X GENOMICS more accurately as focusing exclusively on 10X GENOMICS's fundamentals will not take into account other important factors: 10X GENOMICS DL Company Current Valuation Analysis
10X GENOMICS's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, 10X GENOMICS DL has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Health Information Services (which currently averages 0.0) industry. The current valuation for all Germany stocks is 100.0% higher than that of the company.
10X Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X GENOMICS's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X GENOMICS could also be used in its relative valuation, which is a method of valuing 10X GENOMICS by comparing valuation metrics of similar companies.10X GENOMICS is currently under evaluation in current valuation category among its peers.
10X Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Shares Owned By Institutions | 99.56 % | |||
| Revenue | 503.71 M | |||
| Gross Profit | 416.4 M | |||
| EBITDA | (117.15 M) | |||
| Net Income | (504.02 M) | |||
| Cash And Equivalents | 621.96 M | |||
| Cash Per Share | 5.66 X | |||
| Total Debt | 70.82 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 6.69 X | |||
| Book Value Per Share | 6.78 X | |||
| Cash Flow From Operations | (219.4 M) | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 197.56 | |||
| Number Of Employees | 1.24 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 5.23 B | |||
| Z Score | 43.8 |
About 10X GENOMICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X GENOMICS DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X GENOMICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X GENOMICS DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.